Insmed Incorporated (INSM) Stock Analysis & Investment Frameworks
Insmed Incorporated (INSM) stock analysis on Invetso. Review Insmed Incorporated’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Insmed Incorporated Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Insmed Incorporated Key Financial Metrics
- Market Cap: $25.10B
- Revenue: $606.42M
- ROE: -82.75%
- ROIC: -32.75%
- Dividend Yield: N/A
About Insmed Incorporated
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Insmed Incorporated Investment Frameworks
Invetso analyzes Insmed Incorporated (INSM) across the following frameworks:
- Insmed Incorporated 10Y Growth Potential
- Insmed Incorporated Scenario Analysis
- Insmed Incorporated Risks & Opportunities
- Insmed Incorporated Economic Moat
- Insmed Incorporated Business Model
- Insmed Incorporated Management
- Insmed Incorporated SWOT Analysis
- Insmed Incorporated Porter's 5 Forces
- Insmed Incorporated PESTLE Analysis
- Insmed Incorporated ESG Analysis